Investigational New Drug
Investigational New Drug (IND) is a term used in the pharmaceutical industry to describe a new drug that is under investigation but has not yet been approved by the Food and Drug Administration (FDA) for general use. The IND application is the means by which a pharmaceutical company obtains permission to start human clinical trials and to ship an experimental drug across state lines before a marketing application for the drug has been approved.
Overview[edit | edit source]
The IND application is part of the FDA's drug approval process, in which the agency reviews the proposed testing protocol and evaluates data from animal testing and manufacturing information to ensure that the company can adequately produce and supply the drug. The FDA also reviews the drug's safety data and the proposed clinical study protocols to determine whether the drug's potential benefits outweigh its risks.
Process[edit | edit source]
The IND application process involves several steps. First, the pharmaceutical company must conduct preclinical testing, which includes laboratory and animal testing, to evaluate the drug's safety and effectiveness. The results of these tests are then submitted to the FDA in the IND application.
Once the IND application is submitted, the FDA has 30 days to review the application. If the FDA does not object within this time, the pharmaceutical company can begin clinical trials. These trials are conducted in three phases, each with a different purpose and number of participants.
Phase I trials involve a small group of healthy volunteers and are designed to evaluate the drug's safety, dosage range, and side effects. Phase II trials involve a larger group of patients and are designed to evaluate the drug's effectiveness and further assess its safety. Phase III trials involve a large group of patients and are designed to confirm the drug's effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug to be used safely.
See also[edit | edit source]
References[edit | edit source]
| Investigational New Drug Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
